Published in Addiction on February 01, 2005
Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 3.52
HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. J Acquir Immune Defic Syndr (2014) 1.79
Drug treatment as HIV prevention: a research update. J Acquir Immune Defic Syndr (2010) 1.79
Integration and co-location of HIV/AIDS, tuberculosis and drug treatment services. Int J Drug Policy (2007) 1.65
Retention of participants in medication-assisted programs in low- and middle-income countries: an international systematic review. Addiction (2013) 1.64
Opportunities to diagnose, treat, and prevent HIV in the criminal justice system. J Acquir Immune Defic Syndr (2010) 1.62
Addressing the HIV/AIDS epidemic among Puerto Rican people who inject drugs: the need for a multiregion approach. Am J Public Health (2014) 1.62
"We fear the police, and the police fear us": structural and individual barriers and facilitators to HIV medication adherence among injection drug users in Kiev, Ukraine. AIDS Care (2010) 1.60
Facilitating entry into drug treatment among injection drug users referred from a needle exchange program: Results from a community-based behavioral intervention trial. Drug Alcohol Depend (2005) 1.50
Integrating buprenorphine treatment into office-based practice: a qualitative study. J Gen Intern Med (2008) 1.45
Linking HIV-positive jail inmates to treatment, care, and social services after release: results from a qualitative assessment of the COMPASS Program. J Urban Health (2010) 1.35
Prevention of HIV infection among injection drug users in resource-limited settings. Clin Infect Dis (2010) 1.28
Drug treatment as HIV prevention: expanding treatment options. Curr HIV/AIDS Rep (2010) 1.26
Managing la malilla: Exploring drug treatment experiences among injection drug users in Tijuana, Mexico, and their implications for drug law reform. Int J Drug Policy (2010) 1.24
Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction (2010) 1.16
Progress in HIV reduction and prevention among injection and noninjection drug users. J Acquir Immune Defic Syndr (2010) 1.05
Human resource development and capacity-building during China's rapid scale-up of methadone maintenance treatment services. Bull World Health Organ (2013) 1.01
Substance abuse treatment in human immunodeficiency virus: the role of patient-provider discussions. J Subst Abuse Treat (2008) 1.01
Methadone tolerance testing in drug misusers. BMJ (2006) 1.01
Characterization of the emerging HIV type 1 and HCV epidemics among injecting drug users in Dushanbe, Tajikistan. AIDS Res Hum Retroviruses (2009) 0.99
The North American Opiate Medication Initiative (NAOMI): profile of participants in North America's first trial of heroin-assisted treatment. J Urban Health (2008) 0.99
The therapeutic workplace to promote treatment engagement and drug abstinence in out-of-treatment injection drug users: a randomized controlled trial. Prev Med (2014) 0.97
Mitigating risky sexual behaviors among Russian narcology hospital patients: the PREVENT (Partnership to Reduce the Epidemic Via Engagement in Narcology Treatment) randomized controlled trial. Addiction (2008) 0.96
Pharmacogenomics of CYP3A: considerations for HIV treatment. Pharmacogenomics (2009) 0.93
Forced withdrawal from methadone maintenance therapy in criminal justice settings: a critical treatment barrier in the United States. J Subst Abuse Treat (2013) 0.92
Impact of methadone with versus without drug abuse counseling on HIV risk: 4- and 12-month findings from a clinical trial. J Addict Med (2012) 0.90
Achieving a high coverage--the challenge of controlling HIV spread in heroin users. Harm Reduct J (2007) 0.89
Methadone maintenance treatment and mortality in HIV-positive people who inject opioids in China. Bull World Health Organ (2013) 0.89
Pharmacological pain control for human immunodeficiency virus-infected adults with a history of drug dependence. J Subst Abuse Treat (2007) 0.87
Paying for prevention: challenges to health insurance coverage for biomedical HIV prevention in the United States. Am J Law Med (2012) 0.85
Employment-based abstinence reinforcement promotes opiate and cocaine abstinence in out-of-treatment injection drug users. J Appl Behav Anal (2014) 0.84
Internalized HIV and Drug Stigmas: Interacting Forces Threatening Health Status and Health Service Utilization Among People with HIV Who Inject Drugs in St. Petersburg, Russia. AIDS Behav (2016) 0.83
Nurse practitioner and physician assistant interest in prescribing buprenorphine. J Subst Abuse Treat (2007) 0.82
Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders. Ther Drug Monit (2011) 0.81
Long-term effects of methadone maintenance treatment with different psychosocial intervention models. PLoS One (2014) 0.81
Association between risk behaviors and antiretroviral resistance in HIV-infected patients receiving opioid agonist treatment. J Addict Med (2013) 0.79
HIV risks and seroprevalence among Mexican American injection drug users in California. AIDS Behav (2011) 0.79
Biomedical HIV Prevention Including Pre-exposure Prophylaxis and Opiate Agonist Therapy for Women Who Inject Drugs: State of Research and Future Directions. J Acquir Immune Defic Syndr (2015) 0.78
HIV/AIDS and drug use in China--interactions, impacts, and issues. Subst Use Misuse (2012) 0.78
Exploring stakeholder perceptions of facilitators and barriers to using needle exchange programs in Yunnan Province, China. PLoS One (2014) 0.77
Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058. J Acquir Immune Defic Syndr (2015) 0.77
Generating trust: Programmatic strategies to reach women who inject drugs with harm reduction services in Dar es Salaam, Tanzania. Int J Drug Policy (2016) 0.75
Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders. Curr Vasc Pharmacol (2016) 0.75
Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction. Ann Intern Med (2007) 5.68
Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry (2011) 3.15
Brief intervention for hazardous and harmful drinkers in the emergency department. Ann Emerg Med (2008) 3.12
Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates. Drug Alcohol Depend (2007) 2.99
Cellular microRNA expression correlates with susceptibility of monocytes/macrophages to HIV-1 infection. Blood (2008) 2.96
A brief intervention reduces hazardous and harmful drinking in emergency department patients. Ann Emerg Med (2012) 2.68
Randomized, controlled evaluation of a prototype informed consent process for HIV vaccine efficacy trials. J Acquir Immune Defic Syndr (2003) 2.60
Does an index composed of clinical data reflect effects of inflammation, coagulation, and monocyte activation on mortality among those aging with HIV? Clin Infect Dis (2012) 2.45
Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J Gen Intern Med (2007) 2.38
Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med (2007) 2.38
Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients. Clin Infect Dis (2014) 2.24
Gender and non-medical use of prescription opioids: results from a national US survey. Addiction (2007) 2.15
An evidence-based guide to writing grant proposals for clinical research. Ann Intern Med (2005) 2.13
The prevalence and impact of alcohol problems in major depression: a systematic review. Am J Med (2005) 1.98
HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr (2011) 1.97
Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat (2008) 1.89
The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? Drug Alcohol Depend (2005) 1.72
A randomized trial of audio computer and in-person interview to assess HIV risk among drug and alcohol users in Rio De Janeiro, Brazil. J Subst Abuse Treat (2006) 1.72
A multisite study of the prevalence of HIV with rapid testing in mental health settings. Am J Public Health (2014) 1.67
A trial of integrated buprenorphine/naloxone and HIV clinical care. Clin Infect Dis (2006) 1.62
Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend (2009) 1.56
Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients. J Acquir Immune Defic Syndr (2011) 1.52
Gambling: an addictive behavior with health and primary care implications. J Gen Intern Med (2002) 1.52
The Physician Clinical Support System-Buprenorphine (PCSS-B): a novel project to expand/improve buprenorphine treatment. J Gen Intern Med (2010) 1.51
Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population. J Clin Psychiatry (2015) 1.51
Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther (2004) 1.46
Integrating buprenorphine treatment into office-based practice: a qualitative study. J Gen Intern Med (2008) 1.45
Federal plan for prescriber education on opioids misses opportunities. Ann Intern Med (2012) 1.45
Women and opioid dependence treatment: office-based versus opioid treatment program-based care? Subst Abus (2007) 1.42
Alcohol problems and health care services use in human immunodeficiency virus (HIV)-infected and HIV-uninfected veterans. Med Care (2006) 1.41
Buprenorphine: considerations for pain management. J Pain Symptom Manage (2005) 1.40
Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Subst Abuse Treat (2007) 1.38
Food insecurity is associated with poor virologic response among HIV-infected patients receiving antiretroviral medications. J Gen Intern Med (2011) 1.37
Increased hospital and emergency department utilization by individuals with recent criminal justice involvement: results of a national survey. J Gen Intern Med (2014) 1.35
Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study. Drug Alcohol Depend (2013) 1.33
Examining racial disparities in HIV: lessons from sexually transmitted infections research. J Acquir Immune Defic Syndr (2008) 1.32
Development and implementation of an emergency practitioner-performed brief intervention for hazardous and harmful drinkers in the emergency department. Acad Emerg Med (2005) 1.31
Childhood sexual and physical abuse histories, PTSD, depression, and HIV risk outcomes in women injection drug users: a potential mediating pathway. Am J Addict (2007) 1.31
The next therapeutic challenge in HIV: polypharmacy. Drugs Aging (2013) 1.30
Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend (2008) 1.30
Narrative review: buprenorphine for opioid-dependent patients in office practice. Ann Intern Med (2008) 1.30
Acceptability of audio computer-assisted self-interview (ACASI) among substance abusers seeking treatment in Rio de Janeiro, Brazil. Drug Alcohol Depend (2006) 1.28
Patient satisfaction with primary care office-based buprenorphine/naloxone treatment. J Gen Intern Med (2007) 1.27
Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial. Ann Intern Med (2010) 1.27
Homelessness and HIV risk behaviors among injection drug users. J Urban Health (2004) 1.25
Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence. Clin Infect Dis (2005) 1.24
Patterns of drug use and abuse among aging adults with and without HIV: a latent class analysis of a US Veteran cohort. Drug Alcohol Depend (2010) 1.23
Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. Drug Alcohol Depend (2003) 1.23
A research agenda for enhancing appropriate opioid prescribing in primary care. J Gen Intern Med (2013) 1.23
The association between marijuana smoking and lung cancer: a systematic review. Arch Intern Med (2006) 1.21
Behind the cascade: analyzing spatial patterns along the HIV care continuum. J Acquir Immune Defic Syndr (2013) 1.19
Initial strategies for integrating buprenorphine into HIV care settings in the United States. Clin Infect Dis (2006) 1.19
Provider satisfaction with office-based treatment of opioid dependence: a systematic review. Subst Abus (2005) 1.18
Opioid-prescribing practices and provider confidence recognizing opioid analgesic abuse in HIV primary care settings. J Acquir Immune Defic Syndr (2011) 1.17
Not just the needle: the state of HIV-prevention science among substance users and future directions. J Acquir Immune Defic Syndr (2013) 1.16
Race and distance effects on regular syringe exchange program use and injection risks: a geobehavioral analysis. Am J Public Health (2010) 1.14
The BHIVES collaborative: organization and evaluation of a multisite demonstration of integrated buprenorphine/naloxone and HIV treatment. J Acquir Immune Defic Syndr (2011) 1.14
The effects of federal parity on substance use disorder treatment. Am J Manag Care (2014) 1.13
Morphine enhances HIV infection of neonatal macrophages. Pediatr Res (2003) 1.13
The association between chronic pain and prescription drug abuse in Veterans. Pain Med (2009) 1.12
Alcohol potentiates hepatitis C virus replicon expression. Hepatology (2003) 1.11
Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative. J Acquir Immune Defic Syndr (2011) 1.10
The association between cocaine use and treatment outcomes in patients receiving office-based buprenorphine/naloxone for the treatment of opioid dependence. Am J Addict (2010) 1.10
Alcohol consumption and depressive symptoms over time: a longitudinal study of patients with and without HIV infection. Drug Alcohol Depend (2011) 1.10
Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. J Acquir Immune Defic Syndr (2011) 1.09
A meta-analysis of the efficacy of nonphysician brief interventions for unhealthy alcohol use: implications for the patient-centered medical home. Am J Addict (2011) 1.07
Alcohol potentiates HIV-1 infection of human blood mononuclear phagocytes. Alcohol Clin Exp Res (2002) 1.06
Non-medical use, abuse and dependence on sedatives and tranquilizers among U.S. adults: psychiatric and socio-demographic correlates. Drug Alcohol Depend (2007) 1.04
Evaluation of a combined online and in person training in the use of buprenorphine. Subst Abus (2006) 1.04
Pain and associated substance use among opioid dependent individuals seeking office-based treatment with buprenorphine-naloxone: a needs assessment study. Am J Addict (2013) 1.04
Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care (2011) 1.03
Previous use of alcohol, cigarettes, and marijuana and subsequent abuse of prescription opioids in young adults. J Adolesc Health (2012) 1.02
Receipt of opioid analgesics by HIV-infected and uninfected patients. J Gen Intern Med (2012) 1.02
Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine. J Acquir Immune Defic Syndr (2011) 1.02
Opioids, chronic pain, and addiction in primary care. J Pain (2010) 1.02
Comparing alcohol screening measures among HIV-infected and -uninfected men. Alcohol Clin Exp Res (2012) 1.01
Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches? CNS Drugs (2008) 1.01
Developing and implementing a multispecialty graduate medical education curriculum on Screening, Brief Intervention, and Referral to Treatment (SBIRT). Subst Abus (2012) 1.00
Multi-center trial of baclofen for abstinence initiation in severe cocaine-dependent individuals. Drug Alcohol Depend (2009) 1.00
Training HIV physicians to prescribe buprenorphine for opioid dependence. Subst Abus (2006) 1.00
Opioid use disorder in the United States: insurance status and treatment access. Drug Alcohol Depend (2008) 1.00
Association between alcohol use and HIV viral load. J Acquir Immune Defic Syndr (2011) 0.99
Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals. Drugs (2012) 0.99
Erectile dysfunction drug receipt, risky sexual behavior and sexually transmitted diseases in HIV-infected and HIV-uninfected men. J Gen Intern Med (2009) 0.97
Treatment of adolescent opioid dependence: no quick fix. JAMA (2008) 0.97
Nonmedical use of prescription opioids and pain in veterans with and without HIV. Pain (2011) 0.97
Agreement between electronic medical record-based and self-administered pain numeric rating scale: clinical and research implications. Med Care (2013) 0.97
Buprenorphine for office-based practice: consensus conference overview. Am J Addict (2004) 0.96
A randomized, double-blind, placebo-controlled trial of RBP-8000 in cocaine abusers: pharmacokinetic profile of rbp-8000 and cocaine and effects of RBP-8000 on cocaine-induced physiological effects. J Addict Dis (2014) 0.96
A randomized trial of primary intensive care to reduce hospital admissions in patients with high utilization of inpatient services. Dis Manag (2006) 0.96
Faculty development in small-group teaching skills associated with a training course on office-based treatment of opioid dependence. Subst Abus (2004) 0.96
Naltrexone inhibits alcohol-mediated enhancement of HIV infection of T lymphocytes. J Leukoc Biol (2006) 0.95
Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. J Gen Intern Med (2012) 0.95
Nonmedical use of opioid analgesics obtained directly from physicians: prevalence and correlates. Arch Intern Med (2011) 0.95
Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care. J Acquir Immune Defic Syndr (2011) 0.94
Selectively willing and conditionally able: HIV vaccine trial participation among women at "high risk" of HIV infection. Vaccine (2011) 0.94
Hepatitis C and HIV infections: implications for clinical care in injection drug users. Am J Addict (2004) 0.93
Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone. Alcohol Clin Exp Res (2011) 0.92
Prevalence and correlates for nonmedical use of prescription opioids among urban and rural residents. Drug Alcohol Depend (2012) 0.91